PON1 status evaluation in patients with chronic arterial occlusion of lower limbs due to atherosclerosis obliterans

Archives of Medical Science

Volumn 10, Issue 6, 2014, Pages 1101-1108

  Kasprzak, Magdalena P ^a   Iskra, Maria ^a   Majewski, Wacław ^a   Budzyń Napierała, Magdalena ^a   Gryszczyńska, Bogna ^a   Strzyzewski, Krzysztof ^a   Kasprzak, Jakub ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Raszeja's Hospital   (Poland)

Author keywords

Arylesterase; Low activity phenotype; Paraoxonase activity; Risk of ischemia

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; PHENYLACETIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; HUMAN; HYDROLYSIS; LEG ISCHEMIA; MAJOR CLINICAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHENOTYPE;

EID: 84919968238     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2014.41348     Document Type: Article

References (44)

1. Chait A, Han C, Oram J, Heinecke JW. The immune system and atherogenesis. Lipoprotein associated infam-matory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005; 46: 389-403.
2. Watson AD, Berliner JA, Hama SY, et al. Protective efect of high density lipoprotein associated paraoxonase inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-91.
3. Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST. The paraoxonase gene family and atherosclerosis. Free Radical Biol Med 2005; 38: 153-63.
4. Li HL, Liu D P, Liang CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 2003; 81: 766-79.
5. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low density lipo-protein. FEBS Lett 1991; 286: 152-4.
6. Shih DM, Gu L, Hama S, et al. Mice lacking serum para-oxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-7.
7. Tward A, Xia YR, Wang X P, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106: 484-90.
8. Shih DM, Xia YR, Wang X P, et al. Combined serum para-oxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000; 275: 17527-35.
9. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Avi-ram M. Paraoxonase (PON1) defciency isassociated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 2003; 34: 774-84.
10. van den Berg SW, Jansen EH, Kruijshoop M, et al. Para-oxonase 1 phenotype distribution and activity difers in subjects with newly diagnosed type 2 diabetes (the CODAM Study). Diab Med 2007; 25: 186-93.
11. Sentí M, Tomás M, Fitó M, et al. Antioxidant paraoxo-nase 1 activity in the metabolic syndrome. J Clin Endo-crinol Metab 2003; 88: 5422-6.
12. Kasprzak M, Iskra M, Majewski W, Wielkoszyński T. Arylesterase and paraoxonase activity of paraoxonase (PON1) afected by ischemia in the plasma of patients with arterial occlusion of the lower limbs. Clin Biochem 2009; 42: 50-6.
13. Keskin M, Dolar E, Dirican M, et al. Baseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: relation to disease severity. Intern Med J 2009; 39: 243-8.
14. Elkiran ET, Mar N, Aygen B, Gursu F, Karaoglu A, Koca S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007; 7: 48.
15. Krzystek-Korpacka M, Salmonowicz B, Boehm D, et al. Paraoxonase 1 (PON1) status in gastroesophageal malignancies and associated paraneoplastic syndromes-connection with infammation. Clin Biochem 2008; 41: 804-11.
16. Deakin S, James R. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci 2004; 107: 435-47.
17. Furlong CE, Suzuki SM, Stevens RC, et al. Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact 2010; 187: 355-61.
18. Roest M, van Himbergen TM, Barendrecht AB, et al. Genetic and environmental determinants of the PON-1 phenotype. Eur J Clin Investig 2007; 37: 187-96.
19. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Pri-mo-Parmo SL, La Du BN. Paraoxonase inhibits high density lipoprotein oxidation and preserves its functions. A possible peroxidative role forparaoxonase. J Clin Invest 1998; 101: 1581-90.
20. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-38.
21. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxo-nase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52: 598-608.
22. Browne RW, Koury ST, Marion S, Wilding G, Muti P, Trev-isan M. Accuracy and biological variation of human serum paraoxonase 1 activity and polymorphism(Q192R) by kinetic enzyme assay. Clin Chem 2007; 53: 310-7.
23. Richter RJ, Jarvik G P, Furlong CE. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol 2009; 235: 1-9.
24. Gluba A, Pietrucha T, Banach M, Piotrowski G, Rysz J. The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. Angiology 2010; 61: 157-65.
25. Mackness M, Durrington P, Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol 2004; 15: 399-404.
26. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk ofcoronary heart disease. Am J Hum Genet 1998; 62: 36-44.
27. Pfohl M, Koch M, Enderle MD, et al. Paraoxonase. Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 1999; 192: 623-7.
28. La Du BN. Future studies of low-activity PON1 pheno-type subjects may reveal how PON1 protects against cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23: 1317-8.
29. Stefanović A, Kotur-Stevuljević J, Spasic S, et al. Association of oxidative stress and paraoxonase status with PROCAM risk score. Clin Biochem 2009; 42: 617-23.
30. Zielaskowska J, Olszewska-Słonina D. The polymorphism of paraoxonase and its efects in physiological and pathological processes. Adv Clin Exp Med 2006; 15: 1073-8.
31. Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heartdisease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21: 1451-7.
32. Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radic Biol Med 2004; 37: 1317-23.
33. Gail PJ, Rozek LS, Brophy VH, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotyp. Arterioscler Thromb Vasc Biol 2000; 20: 2441-7.
34. Gan KN, Smolen A, Eckerson HW, La Du BN. Purifcation of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991; 19: 100-6.
35. Deakin S, Moren X, James RW. HDL Oxidation compromises its infuence on paraoxonase-1 secretion and its capacity to modulate enzyme activity, Arterioscler Thromb Vasc Biol 2007; 27: 1146-52.
36. Yilmaz N. Relationship between paraoxonase and ho-mocysteine: crossroads of oxidative diseases. Arch Med Sci 2012; 8: 138-53.
37. Beltowski J. Protein homocysteinylation: a new mechanism of atherogenesis? Postepy Hig Med Dosw 2005; 59: 392-404.
38. Paragh G, Seres I, Harangi M, et al. Discordance in human paraoxonase-1 gene between phenotypes and genotypes in chronic kidney disease Nephron Clin Pract 2009; 113: 46-53.
39. Patel AB, Pal R, Dewan A. Distribution profle of paraox-onase phenotypes among the Gurajatis. Indian J Hum Genet 2007; 13: 65-8.
40. Mirdamadi H, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G. The human paraoxonase-1 phenotype modifes the efect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol 2008; 66: 366-74.
41. Isles C, Paterson J. Identifying patients at risk for coronary heart disease: implications from trials of lipid-low-ering drug therapy. Q J Med 2000; 93: 567-74.
42. Gaidukov L, Rosenblat M, Aviram M, et al. The 192R/Q polymorphs of serum paraoxonase PON1 difer in HDL binding, lipolactonase stimulation, and cholesterol ef-fux. J Lipid Res 2006; 47: 2492-502.
43. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008; 299: 1265-76.
44. Otocka-Kmiecik A, Mikhailidis D P, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012; 51: 314-24.